The SURMOUNT-1 trial (N=2,539) reported a vomiting rate of 12.2% for tirzepatide 15 mg, lower than the 24.8% seen with semaglutide 2.4 mg in STEP 1, although cross-trial comparisons have significant limitations [16]
J Clin Med 2022;11:378.ArticlePubMedPMC 13
Presently, Retatrutide is not available, but its potential effect is comparable to and might possibly exceed current treatments like Wegovy and Zepbound
Studies in animal models have indicated that BPC-157 research compounds may promote angiogenesis, the formation of new blood vessels, through VEGF-mediated pathways (Chang et al., 2011)
Primarily, these medications decrease postprandial glucagon secretion, slow gastric emptying, and promote appetite suppression as a treatment for type 2 diabetes and obesity